[go: up one dir, main page]

WO2003054218A3 - Nucleotide polymorphisms associated with osteoporosis - Google Patents

Nucleotide polymorphisms associated with osteoporosis Download PDF

Info

Publication number
WO2003054218A3
WO2003054218A3 PCT/US2002/040948 US0240948W WO03054218A3 WO 2003054218 A3 WO2003054218 A3 WO 2003054218A3 US 0240948 W US0240948 W US 0240948W WO 03054218 A3 WO03054218 A3 WO 03054218A3
Authority
WO
WIPO (PCT)
Prior art keywords
osteoporosis
polynucleotides
nucleotide polymorphisms
development
polymorphisms associated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2002/040948
Other languages
French (fr)
Other versions
WO2003054218A2 (en
Inventor
Karen Anne Jones
Ana Valdes
David J Townley
Jonathan Mangion
Nicolas Galwey
Simon Bennett
Ian Mckay
Alan Schafer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Incyte Corp
Original Assignee
Incyte Genomics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Incyte Genomics Inc filed Critical Incyte Genomics Inc
Priority to EP02805650A priority Critical patent/EP1466012A2/en
Priority to AU2002366709A priority patent/AU2002366709A1/en
Priority to CA002471376A priority patent/CA2471376A1/en
Publication of WO2003054218A2 publication Critical patent/WO2003054218A2/en
Publication of WO2003054218A3 publication Critical patent/WO2003054218A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Analytical Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The invention relates to polynucleotides associated with susceptibility to low bone mineral density and/or bone damage generally associated with human diseases, and in particular to osteoporosis. The invention further relates to polymorphic polynucleotides associated with osteoporosis. The invention provides methods of determining if a particular polymorphism predisposes an individual to or is associated with the development of osteoporosis. The invention also provides methods of detecting the presence of one or more polymorphism as an indicator of osteoporosis, and provides for use of novel polynucleotides of the invention in the development of drugs and in disease treatment.
PCT/US2002/040948 2001-12-20 2002-12-19 Nucleotide polymorphisms associated with osteoporosis Ceased WO2003054218A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP02805650A EP1466012A2 (en) 2001-12-20 2002-12-19 Nucleotide polymorphisms associated with osteoporosis
AU2002366709A AU2002366709A1 (en) 2001-12-20 2002-12-19 Nucleotide polymorphisms associated with osteoporosis
CA002471376A CA2471376A1 (en) 2001-12-20 2002-12-19 Nucleotide polymorphisms associated with osteoporosis

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US34271101P 2001-12-20 2001-12-20
US60/342,711 2001-12-20
US42355902P 2002-11-04 2002-11-04
US60/423,559 2002-11-04

Publications (2)

Publication Number Publication Date
WO2003054218A2 WO2003054218A2 (en) 2003-07-03
WO2003054218A3 true WO2003054218A3 (en) 2004-02-19

Family

ID=26993153

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2002/040948 Ceased WO2003054218A2 (en) 2001-12-20 2002-12-19 Nucleotide polymorphisms associated with osteoporosis

Country Status (4)

Country Link
EP (1) EP1466012A2 (en)
AU (1) AU2002366709A1 (en)
CA (1) CA2471376A1 (en)
WO (1) WO2003054218A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0301715D0 (en) * 2003-01-24 2003-02-26 King S College London Detection of predisposition to osteoporosis
DK1644406T3 (en) 2003-07-11 2012-11-19 Develogen Ag Use of DG153 secreted protein products to prevent and treat pancreatic and / or obesity and / or metabolic syndrome
CA3116028A1 (en) * 2018-10-09 2020-04-16 Genecentric Therapeutics, Inc. Detecting tumor mutation burden with rna substrate

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
OHNO ET AL.: "A cDNA cloning of human AEBP1 from primary cultured osteoblasts and its expression in a differentiating osteoblastic cell line", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, vol. 228, 1996, pages 411 - 414, XP002970388 *

Also Published As

Publication number Publication date
AU2002366709A1 (en) 2003-07-09
CA2471376A1 (en) 2003-07-03
EP1466012A2 (en) 2004-10-13
AU2002366709A8 (en) 2003-07-09
WO2003054218A2 (en) 2003-07-03

Similar Documents

Publication Publication Date Title
SG142154A1 (en) Methods for genomic analysis
WO2003054166A3 (en) Nucleotide polymorphisms associated with osteoarthritis
AU2003233451A8 (en) Targets, methods, and reagents for diagnosis and treatment of schizophrenia
GB0418542D0 (en) Integrated biosensor and simulation system for diagnosis and therapy
WO2004047623A3 (en) Methods for identifying risk of breast cancer and treatments thereof
WO2005040421A3 (en) Prognostic and diagnostic markers for cell proliferative disorders of the breast tissues
WO2005001046A3 (en) Methods for predicting the course of a malignant disease
WO2004043232A3 (en) Methods for identifying risk of melanoma and treatments thereof
WO2005014846A3 (en) Methods for identifying risk of breast cancer and treatments thereof
WO2003031942A8 (en) Reagents and methods useful for detecting diseases of the breast
WO2003054218A3 (en) Nucleotide polymorphisms associated with osteoporosis
WO2007067719A3 (en) Diagnosing human diseases by detecting dna methylation changes
WO2003054167A3 (en) Identification of novel polymorphic sites in the human mglur8 gene and uses thereof
DE69938837D1 (en) GENOMIC AND COMPLETE CDNA SEQUENCES OF HUMAN ADIPOCYTES SPECIFIC APM1 AND BIALLELIAN MARKERS THEREOF
WO2003031651A3 (en) Method of determining susceptibility to inflammatory bowel disease
WO2000058510A3 (en) Schizophrenia associated genes, proteins and biallelic markers
WO2004048546A3 (en) Methods for identifying risk of breast cancer and treatments thereof
WO2001096603A3 (en) Methods to identify polynucleotide and polypeptide sequences which may be associated with physiological and medical conditions
DE50111824D1 (en) DIAGNOSIS OF HUMOS ASSOCIATED DISEASES
AU2003218601A1 (en) Phox2b polymorphisms as hirschsprung's disease diagnostic markers and methods based thereon
WO2005112568A3 (en) Haplotype markers and methods of using the same to determine response to treatment
WO2006006853A3 (en) Differences in intestinal gene expression profiles
IL172690A0 (en) Methods for the diagnosis and prognosis of alzheimer's disease
WO2005118834A3 (en) Methods for identifying risk of breast cancer and treatment thereof
WO2004065938A3 (en) Human osteoporosis gene

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2471376

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2002805650

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2002805650

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 2002805650

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP